TGFB1 and idiopathic pulmonary fibrosis: Although TGF-β1 is an attractive target for IPF therapy, few candidates have reached late-phase clinical trials due to their toxicity, e.g., BG00011, a humanized monoclonal antibody directed against integrin αvβ6 (NCT01371305).